Radiosensitizing properties of dual-functionalized carbon nanostructures loaded with temozolomide

• Radmila Milenkovska,
• Nikola Geskovski,
• Dushko Shalabalija,
• Ljubica Mihailova,
• Petre Makreski,
• Dushko Lukarski,
• Igor Stojkovski,
• Maja Simonoska Crcarevska and
• Kristina Mladenovska

Beilstein J. Nanotechnol. 2025, 16, 229–251, doi:10.3762/bjnano.16.18

• incorporation of TMZ in organic and inorganic nanomaterials and their hybrids, designed in a wide variety of shapes such as nanoparticles (NPs), conjugates, dendrimers, and liposomes [35]. With various bioengineering techniques, the nanomaterials’ size, shape, and surface properties were modified to improve

Recent advances in photothermal nanomaterials for ophthalmic applications

• Jiayuan Zhuang,
• Linhui Jia,
• Chenghao Li,
• Rui Yang,
• Jiapeng Wang,
• Wen-an Wang,
• Heng Zhou and
• Xiangxia Luo

Beilstein J. Nanotechnol. 2025, 16, 195–215, doi:10.3762/bjnano.16.16

• conditions of the ICG NPs. Among them, only ICG liposomes synthesized using lipids can induce the production of VNBs. The ICG concentration in PLGA ICG NPs is below 15 μg·mL−1, which is not sufficient to rapidly increase the temperature to produce VNBs. Evaluation of the VNB effect in bovine retinal explants

• showed that ICG liposomes led to subtle disruption effects in the ILM, in which completely ablated ILM regions alternate with intact regions. Photoporation strategies to overcome the ILM have the potential to improve the efficacy of all retinal therapies impeded by ILM delivery barriers, including

• sources, high adjustability, and ease of access, have paved the way for precise and controllable photothermal therapies. Notably, therapeutic platforms that integrate photothermal nanomaterials with drugs, antibodies, liposomes, hydrogels, heat/pH-sensitive materials, and shape memory materials have

Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy

• Naths Grazia Sukubo,
• Paolo Bigini and
• Annalisa Morelli

Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10

• . Intranasal delivery has emerged as a promising strategy for targeting the central nervous system by bypassing the blood–brain barrier (BBB). This approach was demonstrated by the nose-to-brain administration of D6-cholestrol-loaded liposomes, which led to an accumulation of D6-cholesterol in the brain in

• STAT6 inhibitor AS1517499, zoledronic acid, or muramyl tripeptide (MTP), these liposomes inhibited M2 polarization. In preclinical breast cancer models, PAPC nanoliposomes reduced tumor growth, inhibited the M2 phenotype, and prevented pre-metastatic niche formation, achieving up to a 70% reduction in

• inflammation resolution and tissue repair. In IBD, sustaining the M2 phenotype is particularly challenging because of the pro-ferroptotic microenvironment, which undermines macrophage survival. Zhao et al. addressed this issue by developing calcium carbonate (CaCO3)-mineralized liposomes (CLF) loaded with the

Mechanistic insights into endosomal escape by sodium oleate-modified liposomes

• Ebrahim Sadaqa,
• Satrialdi,
• Fransiska Kurniawan and
• Diky Mudhakir

Beilstein J. Nanotechnol. 2024, 15, 1667–1685, doi:10.3762/bjnano.15.131

• .15.131 Abstract Endosomal entrapment significantly limits the efficacy of drug delivery systems. This study investigates sodium oleate-modified liposomes (SO-Lipo) as an innovative strategy to enhance endosomal escape and improve cytosolic delivery in 4T1 triple-negative breast cancer cells. We aimed to

• elucidate the mechanistic role of sodium oleate in promoting endosomal escape and compared the performance of SO-Lipo with unmodified liposomes (Unmodified-Lipo) and Aurein 1.2-modified liposomes (AUR-Lipo). Liposomes were prepared using the thin-film hydration method, resulting in Unmodified-Lipo, SO-Lipo

• measuring the colocalization of labeled liposomes with lysosomal markers, quantified using Pearson’s correlation coefficient. Lipid mixing assays assessed the potential fusogenic effect, and molecular dynamics (MD) simulations explored the interactions of protonated sodium oleate (SO) with the endosomal

Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications

• Hugo Felix Perini,
• Beatriz Sodré Matos,
• Carlo José Freire de Oliveira and
• Marcos Vinicius da Silva

Beilstein J. Nanotechnol. 2024, 15, 1619–1626, doi:10.3762/bjnano.15.127

• differences in key characteristics. The National Nanotechnology Initiative (NNI) emphasizes that nanomaterials hold promising potential across various fields of knowledge [1][5]. Materials such as liposomes, nanoparticles, polymer–drug conjugates, inorganic noble metals, and quantum dots may improve

• is linked to dementia and neuronal loss [70]. Focusing on BBB compatibility, lipid-based nanoparticles demonstrate high potential in facilitating drug delivery. Macrophage membrane-coated liposomes co-modified with the RVG29 peptide and triphenylphosphine cation have shown improved targeting of brain

Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects

• Iqra Rahat,
• Pooja Yadav,
• Aditi Singhal,
• Mohammad Fareed,
• Jaganathan Raja Purushothaman,
• Mohammed Aslam,
• Raju Balaji,
• Sonali Patil-Shinde and
• Md. Rizwanullah

Beilstein J. Nanotechnol. 2024, 15, 1473–1497, doi:10.3762/bjnano.15.118

• biological fluids [51]. During the development of these nanocarriers, the concentration of cationic lipids for the inner core, density of the PEG chain on the outer layer, and molecular weight of the polymers are adjusted to modulate their physicochemical characteristics [52][53]. Polymer-caged liposomes As

• the name suggests, the structural arrangement of these nanocarriers involves the surface coating of liposomes with biodegradable polymers/copolymers. The surface modification not only imparts surface functionality to the nanocarrier but also enhances its therapeutic efficacy by site-specific targeting

• -PLHNPs than that of the free drug. Jøraholmen and co-workers fabricated polymer-coated liposomes using CHS for better topical delivery of RVT to treat vaginal inflammation and infections [109]. The developed RVT-PLHNPs showed excellent mucoadhesive characteristics and sustained drug release. The radical

Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals

• Selin Akpinar Adscheid,
• Akif E. Türeli,
• Nazende Günday-Türeli and
• Marc Schneider

Beilstein J. Nanotechnol. 2024, 15, 1400–1414, doi:10.3762/bjnano.15.113

• ; intranasal delivery; liposomes; nanomedicine; nanostructured lipid carriers (NLCs); polymer nanoparticles; RNA delivery; solid lipid nanoparticles (SLNs); Introduction The central nervous system (CNS) consists of the brain and the spinal cord and is considered the body’s processing and control center. While

• lipid NPs, polymeric NPs, liposomes, emulsions, and novel hybrid NPs and their potential use as DDSs in N2B delivery (Figure 4). Polymeric NPs Because of their tunable physicochemical characteristics, polymeric NPs are a potential vehicle for different drug delivery applications [71]. They can be

• ]. Liposomes Liposomes are another type of DDS that has been extensively investigated over the years [87][88][89]. The structure of a liposome contains a lipid bilayer surrounding an aqueous core, which offers advantages in encapsulating both hydrophobic and hydrophilic substances [90]. The additional

Synthesis, characterization and anticancer effect of doxorubicin-loaded dual stimuli-responsive smart nanopolymers

• Ömür Acet,
• Pavel Kirsanov,
• Burcu Önal Acet,
• Inessa Halets-Bui,
• Dzmitry Shcharbin,
• Şeyda Ceylan Cömert and
• Mehmet Odabaşı

Beilstein J. Nanotechnol. 2024, 15, 1189–1196, doi:10.3762/bjnano.15.96

• than free DOX. To date, several types of nanoparticles, such as liposomes, micelles, and metal-organic frameworks, have been studied to encapsulate DOX to obtain effective and non-toxic drugs [7][8]. Great attention has been paid to nanoparticles because of their specific properties, such as small size

Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

• Damai Ria Setyawati,
• Fransiska Christydira Sekaringtyas,
• Riyona Desvy Pratiwi,
• A’liyatur Rosyidah,
• Rohimmahtunnissa Azhar,
• Nunik Gustini,
• Gita Syahputra,
• Idah Rosidah,
• Etik Mardliyati,
• Tarwadi and
• Sjaikhurrizal El Muttaqien

Beilstein J. Nanotechnol. 2024, 15, 1105–1116, doi:10.3762/bjnano.15.89

• , liver-targeted nanocarriers are needed to increase the drug concentration in the liver with minimum off-target effects. For this purpose, both passive and active targeting strategies of nanomedicine-based drug deliveries have been studied. Liposomes, micelles, solid lipid NPs, and gold NPs are examples

• penetration through biological barriers, leading to the alteration of the drug’s pharmacological activity. Among them, lipid-based NPs, including liposomes, represent the most common nanocarrier platform currently used at the clinical stage for liver fibrosis treatment [21][22][23]. Nanocarrier–liver

• as an absorption enhancer [51]. The therapeutic potential of curcumin using nanoformulations was reviewed by several researchers, summarizing recent curcumin encapsulation works on various NP platforms (liposomes, solid lipid NPs, micelles, and polymeric NPs) [52][53]. For example, polymeric

Entry of nanoparticles into cells and tissues: status and challenges

• Kirsten Sandvig,
• Tore Geir Iversen and
• Tore Skotland

Beilstein J. Nanotechnol. 2024, 15, 1017–1029, doi:10.3762/bjnano.15.83

• intravenous (i.v.) injection is required to benefit from NPs as therapeutics or imaging agents in an optimal way. Many different types of NPs have been made; for an overview, see [1]. Doxorubicin encapsulated in liposomes (Doxil®/Caelyx®) was the first NP-based drug approved for cancer treatment by the US

A review on the structural characterization of nanomaterials for nano-QSAR models

• Salvador Moncho,
• Eva Serrano-Candelas,
• Jesús Vicente de Julián-Ortiz and
• Rafael Gozalbes

Beilstein J. Nanotechnol. 2024, 15, 854–866, doi:10.3762/bjnano.15.71

• structures involving organic polymeric substances (such as nanoplastics and dendrimers) or lipids (such as liposomes). Because of the simpler chemical structure of the components typically found in NMs, the chemical descriptors tend to be also simpler than those of organic molecules. Furthermore, it is

Cholesterol nanoarchaeosomes for alendronate targeted delivery as an anti-endothelial dysfunction agent

• Horacio Emanuel Jerez,
• Yamila Roxana Simioni,
• Kajal Ghosal,
• Maria Jose Morilla and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 517–534, doi:10.3762/bjnano.15.46

• basal compartments. The endocytosis of nanoARC-Chol(ALN), was observed to partly reduce the endothelial-mesenchymal transition of HUVECs. Besides, while 10 mg/mL dexamethasone, 7.6 mM free ALN and ALN-loaded liposomes failed, 50 μg/mL TL + 2.5 μg/mL ALN (i.e., nanoARC-Chol(ALN)) reduced the IL-6 and IL

• interest in the drug delivery field [27][28]. Nanoarchaeosomes (nanoARC) prepared with lipids extracted from H. tebenquichense, for example, are naturally targeted to scavenger receptor A I/II (SRAI/II) expressed by phagocytic cells and certain endothelial cells and outperform liposomes in structural

• compartments, respectively. Our main findings were that the endocytosis of nanoARC-Chol(ALN) by HUVECs reduced the endothelial-mesenchymal transition induced by LPS; also, while dexamethasone, micromolar-free ALN, and ALN-loaded HSPC-Chol liposomes failed, nanoARC-Chol(ALN) strongly reduced the production of

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• still required regarding a realistic use of nanomedicines effective against CD. Keywords: benznidazole; liposomes; nanocrystals; nanomedicines; nanoparticles; Trypanosoma cruzi; Introduction Nanomedicines are used to solve the problems posed by poor solubility and/or permeability and high toxicity of

• countries’ institutions (Brazil and Argentina), and private pharmaceutical companies. The project started proposing a sublingual formulation of BNZ within liposomes or lipid nanoparticles, assuming the intact formulations could reach the blood, avoid the hepatic first-pass metabolism, and reduce the

• toxicity of BNZ. The project, however, failed in its attempt to incorporate BNZ into liposomes, while lipid nanoparticles could not be formulated into sublingual tablets. The project changed to formulate BNZ/hydroxypropyl-β-cyclodextrin complexes. These complexes were prepared on a scale seven times larger

Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics

• Phuong-Thao Dang-Luong,
• Hong-Phuc Nguyen,
• Loc Le-Tuan,
• Xuan-Thang Cao,
• Vy Tran-Anh and
• Hieu Vu Quang

Beilstein J. Nanotechnol. 2024, 15, 180–189, doi:10.3762/bjnano.15.17

• cytoskeleton and chlorambucil (CHL) inhibits DNA synthesis. These drugs can be encapsulated inside nanoparticles for administration to increase the stability of the medication in circulation and therapeutic efficacy. For example, doxorubicin can be inserted into liposomes and paclitaxel attaches to the protein

Berberine-loaded polylactic acid nanofiber scaffold as a drug delivery system: The relationship between chemical characteristics, drug-release behavior, and antibacterial efficiency

• Le Thi Le,
• Hue Thi Nguyen,
• Liem Thanh Nguyen,
• Huy Quang Tran and
• Thuy Thi Thu Nguyen

Beilstein J. Nanotechnol. 2024, 15, 71–82, doi:10.3762/bjnano.15.7

• been employed to produce nanoformulations of drugs for endowing a better therapeutic effect. The nanoformulations for drug delivery can be designed using nanocarrier systems, including organic materials (liposomes, nanoemulsions, nanomicelles, and nanofibers) and inorganic nanoparticles (gold, silver

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review

• Douglas Dourado,
• Thayse Silva Medeiros,
• Éverton do Nascimento Alencar,
• Edijane Matos Sales and
• Fábio Rocha Formiga

Beilstein J. Nanotechnol. 2024, 15, 37–50, doi:10.3762/bjnano.15.4

• , lipid nanoparticles, nano- and microemulsions, liposomes, or metallic nanoparticles [68]. Costa-Lima and colleagues incorporated bisnaphthalimidopropyldiaaminooctane (BNIPDaoct) into PLGA polymeric nanoparticles and obtained particles with sizes around 150 nm, with encapsulation efficiency around 90

• liposomes: 20–100 nm and large liposomes: >100 nm) are capable of loading both hydrophilic and lipophilic drugs [82][83]. Leishmanial drugs, such as miltefosine [84], buparvaquone [85], nitazoxanide [86], artemisinin [75], berberine [87], and paromomycin [88] have already been successfully loaded into

Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• homogenization); (2) low-energy methods, which requires the precipitation of nanoparticles from homogeneous systems (such as microemulsions); and (3) methods based on organic solvents (emulsification–diffusion method) [35]. Liposomes are vesicles composed of a phospholipid and cholesterol with an aqueous core

• molecule, and excellent biocompatibility and safety [38]. Liposomes can also be modified to selectively deliver a drug to a specific site. This is very valuable because it can reduce potential side effects and increase the maximum tolerated dose, which improves therapeutic benefits [39]. For example

• liposomes, exposes them to degradation by stomach acid, bile salts, and enzymes. Consequently, in in vivo models, intact liposomes may encounter challenges to reach the bloodstream owing to the adverse conditions of the stomach [42]. This elucidates why, in in vitro tests, the author exclusively assessed

Fluorescent bioinspired albumin/polydopamine nanoparticles and their interactions with Escherichia coli cells

• Eloïse Equy,
• Jordana Hirtzel,
• Sophie Hellé,
• Béatrice Heurtault,
• Eric Mathieu,
• Morgane Rabineau,
• Vincent Ball and
• Lydie Ploux

Beilstein J. Nanotechnol. 2023, 14, 1208–1224, doi:10.3762/bjnano.14.100

• of antimicrobial resistance of bacteria [5], this appears as a promising route to deliver antimicrobials while reducing the drug doses and subsequent harmful side effects in antibacterial applications. To this end, different types of ONPs have been used, such as liposomes [6] and nanoparticles (NPs

• nanoplastics can penetrate and accumulate in bacterial cells [22], thus suggesting that other ONPs may have a similar fate in bacteria. In general, the mechanisms of action of ONPs used as drug nanocarriers in antibacterial applications are expected to vary with the nanoparticle type (e.g., liposomes or PLGA

• , but the penetration of liposomes into the cell was not proved [25]. In general, organic nanocarriers are often reported to penetrate mammalian cells infected by bacteria, improving the drug accumulation in these eukaryotic cells and increasing the antibacterial efficiency of the drug [3][4][9][26

Elasticity, an often-overseen parameter in the development of nanoscale drug delivery systems

• Agnes-Valencia Weiss and
• Marc Schneider

Beilstein J. Nanotechnol. 2023, 14, 1149–1156, doi:10.3762/bjnano.14.95

• -loaded gelatin nanoparticles imaged in the quantitative imaging mode with a JPK NanoWizard III in Milli-Q® water at 37 °C, as well as the extracted Young’s modulus map as previously described [22] (Figure 1). Takechi-Haraya et al. showed that for liposomes both methods deliver the same results [21]. The

• with a model hydrogel that there is a higher penetration for more deformable extracellular vesicles from mouse mesenchymal stromal cells [37]. A second study, from Yu et al., shows rigidity-dependent penetration of lipid NPs in the mucus layer of rat intestinal mucus. Liposomes were either hollow or

• particles showed better cellular uptake if no mucus layer was present. In contrast to this, the cellular uptake for semielastic particles was not significantly affected by the presence of a mucus layer [38]. Liposomes with PLGA cores were used by Yu et al. to increase the stiffness in combination with

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies

• Giuliana Muraca,
• María Esperanza Ruiz,
• Rocío C. Gambaro,
• Sebastián Scioli-Montoto,
• María Laura Sbaraglini,
• Gisel Padula,
• José Sebastián Cisneros,
• Cecilia Yamil Chain,
• Vera A. Álvarez,
• Cristián Huck-Iriart,
• Guillermo R. Castro,
• María Belén Piñero,
• Matias Ildebrando Marchetto,
• Catalina Alba Soto,
• Germán A. Islan and
• Alan Talevi

Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66

• efficiently. Many developments have been made in the past years resulting in lipid formulations such as liposomes, solid lipid nanoparticles (SLNs), and nanoemulsions, which increased the apparent solubility of BNZ and its efficacy against parasites [17]. Remarkably, oil-in-water nanoemulsions improved the

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• surface, triggered by protease degradation after tumor homing by the EPR effect [112]. Mesoporous silica vesicles (MSVs; dav = 3 μm) with high affinity to tumor vasculature were also described by Blanco et al. as a platform for the triggered release of various therapeutic nanoscale vectors (liposomes

Facile preparation of Au- and BODIPY-grafted lipid nanoparticles for synergized photothermal therapy

• Yuran Wang,
• Xudong Li,
• Haijun Chen and
• Yu Gao

Beilstein J. Nanotechnol. 2022, 13, 1432–1444, doi:10.3762/bjnano.13.118

• delivery systems through van der Waals forces, hydrogen bonds, π–π stacking, or electrostatic or hydrophobic interactions [24]. Several BODIPYs have been reported to be loaded into liposomes for cancer therapy [25]. Therefore, we speculated that BODIPY can be associated with our previously reported

Microneedle-based ocular drug delivery systems – recent advances and challenges

• Piotr Gadziński,
• Anna Froelich,
• Monika Wojtyłko,
• Antoni Białek,
• Julia Krysztofiak and
• Tomasz Osmałek

Beilstein J. Nanotechnol. 2022, 13, 1167–1184, doi:10.3762/bjnano.13.98

• introduced into systems whose purpose is to provide the expected concentration in the treated tissue for the desired time period. The most frequently studied and described are liposomes [60][61], micelles [60][62], microparticles [63][64][65], nanoparticles [66][67], micro- [68][69], and nanoemulsions [70

Ethosomal (−)-epigallocatechin-3-gallate as a novel approach to enhance antioxidant, anti-collagenase and anti-elastase effects

• Çiğdem Yücel,
• Gökçe Şeker Karatoprak,
• Sena Yalçıntaş and
• Tuğba Eren Böncü

Beilstein J. Nanotechnol. 2022, 13, 491–502, doi:10.3762/bjnano.13.41

• noted that the degradation of EGCG under UV was delayed by the ETHs and by the incorporation of tocopherol as an antioxidant in the formulation [35]. In another study, cream-based formulations of different vesicular systems (liposomes, ethosomes, and transfersomes) containing Curcuma longa extract were

• liposomes, which have limited skin penetration and mostly remain in the upper layer of the stratum corneum. The release of the therapeutic agent occurs by the fusion of these vesicles with the cell membranes in the deeper layers of the skin [11]. ETHs have been reported to help many active substances to be

• in comparison to studies using liposomes. An improvement of 81.84% was achieved in the area affected by psoriasis [34]. Likewise, it can be said that better therapeutic results are obtained with ethosomal-based systems. Kaur and Saraf prepared and characterized different vesicular systems (liposomes

Micro- and nanotechnology in biomedical engineering for cartilage tissue regeneration in osteoarthritis

• Zahra Nabizadeh,
• Mahmoud Nasrollahzadeh,
• Hamed Daemi,
• Mohamadreza Baghaban Eslaminejad,
• Ali Akbar Shabani,
• Mehdi Dadashpour,
• Majid Mirmohammadkhani and
• Davood Nasrabadi

Beilstein J. Nanotechnol. 2022, 13, 363–389, doi:10.3762/bjnano.13.31

• delivery [50], in vitro diagnosis [51], in vivo imaging [52], and TE purposes. Various NPs can be prepared in the form of liposomes, nanocapsules, micelles, dendrimers, and nanospheres based on their composition and method of preparation. Basically, NPs are designed to function as carriers for bioactive